AmerisourceBergen Corporation

AmerisourceBergen managed to exceed analyst expectations in terms of revenue as well as earnings. The company had a sales growth of approximately 10% and adjusted EPS increase of 9%. Its business fundamentals remain robust as it capitalizes on opportunities from its pharmaceutical-centric strategy and expertise. Their successes continue to highlight the worth of their pharmaceutical-centric strategy, which includes critical strategic relationships, specialist leadership, and full global commercialization services. A key strategic decision of the management during the quarter was the investment in OneOncology, a network of top community oncologists with 900 member providers in 14 states. This deal is anticipated to strengthen and expand AmerisourceBergen’s relationships with community providers. OneOncology’s practice management services also complement the company’s existing inventory management, practice analytics, and clinical trial support capabilities. During the quarter, they announced the opening of their Cell and Gene Therapy Integration Hub, a new, platform-independent system that supports cell and gene therapy developers throughout the entire product life cycle, from clinical trials to specialized logistics services, market access plans, and patient support services. The acquisition of PharmaLex also enhanced their portfolio of tools to help pharma companies, large and small, through the development process. We give AmerisourceBergen Corporation a ‘Hold’ rating with a revised target price.